𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Invasive breast cancer cells exhibit increased mobility of the actin-binding protein CapG

✍ Scribed by Malte Renz; Beate Betz; Dieter Niederacher; Hans Georg Bender; Jörg Langowski


Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
282 KB
Volume
122
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The CapG protein, a Gelsolin‐related actin‐binding protein, is expressed at higher levels in breast cancer, especially in metastasizing breast cancer, than in normal breast epithelium. Furthermore, it is known that an increased expression of the CapG protein triggers an increase in cell motility. According to in vitro experiments, it was supposed that it is the nuclear fraction of the protein, which causes the increase in cell motility. Here, we examined the dynamical distribution of the CapG protein within the living cell, i.e. the import of the CapG protein into the nucleus. The nuclear import kinetics of invasive, metastasizing breast cancer cells were compared to the import kinetics of non‐neoplastic cells similar to normal breast epithelium. FRAP kinetics showed a highly significant increase in the recovery of photobleached CapG–eGFP in the cancer cells, so that a differentiation of invasive, metastasizing cells and non‐invasive, non‐metastasizing cells on the basis of transport processes of the CapG protein between the nucleus and the cytoplasm seems to be possible. Comprehension of the mobility and compartmentalization of the CapG protein in normal and in cancer cells in vivo could constitute a new basis to characterize the invasiveness and metastasizing potential of breast cancer. © 2007 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Invasiveness of breast cancer cells MDA-
✍ Benoit Paquette; Martine Bisson; Catherine Baptiste; Hélène Therriault; Rosalie 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 121 KB

In malignant breast cancer, estrogen metabolism is altered, favoring the accumulation of hydroxyestradiols, which can generate free radicals. These reactive species can activate matrix metalloproteinases (MMPs), which in turn can hydrolyze the proteins of the extracellular matrix (ECM) that act as a

Increased expression of the transcriptio
✍ Katarina Rask; Magnus Thörn; Fredrik Pontén; Wolfgang Kraaz; Karin Sundfeldt; La 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 211 KB 👁 2 views

Regulation of cell differentiation is most often impaired in malignant tumors and may represent a key mechanism for the progression of the disease. CCAAT-enhancer binding protein (C/EBP) is a family of transcription factors involved in the regulation of embryonic gut development in rodents, which ha

Novel nuclear matrix protein HET binds t
✍ Steffi Oesterreich; Adrian V. Lee; Toby M. Sullivan; Shanti K. Samuel; James R. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

Since the small heat shock protein hsp27 enhances both growth and drug resistance in breast cancer cells, and is a bad prognostic factor in certain subsets of breast cancer patients, we have characterized the transcriptional regulation of hsp27, with the long-term goal of targeting its expression cl

Ectopic expression of the ErbB-3 binding
✍ Tracy J. Lessor; Joo-Yeon Yoo; Xianmin Xia; Nicholas Woodford; Anne W. Hamburger 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 2 views

Ebp1, an ErbB-3 binding protein, translocates from the cytoplasm to the nucleus of human breast cancer cells after treatment with the ErbB-3 ligand, heregulin. The purpose of these studies was to examine the effects of ectopic expression of ebp1 on the biological properties of human ErbB-3-expressin

CCAAT/enhancer binding protein δ (C/EBPδ
✍ G.S. Sivko; J.W. DeWille 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 1 views

## Abstract “Loss of function” alterations in growth inhibitory signal transduction pathways are common in cancer cells. In this study, we show that growth arrest (GA) treatments—serum and growth factor withdrawal and growth inhibitory IL‐6 family cytokines (Interleukin‐6 and Oncostatin M (OSM))—in